Company intelligence / Profile preview

Tianjin Conjustar Biotechnology Co., Ltd.

Ownership: Private
Development stage: Other

Overview

Tianjin Conjustar has advanced two main peptide-drug conjugate oncology assets into Phase 1 clinical trials in China, targeting solid tumors and neoplasms. SC‑101 received IND approval from both China's NMPA and the US FDA in 2024, while SC‑102 entered Phase I trials for metastatic solid tumors. The company is developing a total of five oncology pipeline programs with a focus on improving drug delivery and efficacy over existing ADC therapies. No published late-stage or pivotal results as of May 2025.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADC)Peptide-drug conjugates (PDC)Chemical drugs
Industry: Biotech

Drug pipeline

3 assets

SC-101

2 more assets in the full pipeline.

Partnerships

Incubated by Fosun Health Capital New Drug FundWuXi AppTec

Beyond the preview

Go deeper on Tianjin Conjustar Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin Conjustar Biotechnology Co., Ltd..